Gilead signs deals with Indian companies for low-cost HIV drug
(Reuters) - Gilead Sciences Inc signed deals with three Indian companies to drive sales and reduce manufacturing costs of low-cost generic versions of its HIV drug emtricitabine in developing countries.
Under deals with Ranbaxy Laboratories, Strides Arcolab and Mylan Inc's India unit, Gilead will provide technology and funding to help reduce manufacturing costs of the drug, the companies said.
Gilead, which sells the drug under the Emtriva brand, is the world's largest maker of branded drugs to treat the human immunodeficiency virus -- the cause of AIDS.
(Reporting by Shailesh Kuber; Editing by Viraj Nair)
- Tweet this
- Share this
- Digg this
- China should set lower 2015 GDP growth target of 6.5-7 pct - IMF
- Netanyahu vows to complete Gaza tunnels destruction
- U.S. says hopeful of WTO deal with India only hours before deadline
- Cricket - India four down and facing England defeat
- UPDATE 2-Argentina defaults but investors see deal possible eventually
Liberia will close schools and consider quarantining some communities, it said on Wednesday, rolling out the toughest measures yet imposed by a West African government to halt the worst outbreak on record of the deadly Ebola virus. Full Article